Interstitial Lung DiseaseNCT06522334
Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria
An observational study of Interstitial Lung Disease, run by Ludwig Boltzmann Institute for Lung Health at 5 sites in Austria.
Trial summary
The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Interstitial Lung Disease
- How many people
- 400 participants
- Where
- 5 sitesAustria
- Study dates
- 28 Feb 2024to 28 Feb 2034
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Everybody with a diagnosis of interstitial lung disease, over 18 years old will be asked to participate.
Who may be able to join
- diagnosis of interstitial lung disease
- written informed consent
Who cannot join
- to not comprehend and rightfully judge participation
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Austria5 sites, 5 recruiting
- Recruiting
Klinik Hietzing
Vienna, 1130
Robab Breyer-Kohansal, +431 80110 2471, robab.breyer-kohansal@lunghealth.lbg.ac.at
Katharina Marth, katharina.marth@gesundheitsverbund.at
- Recruiting
Klinik Penzing
Vienna, 1140
Marie-Kathrin Breyer, 019106042002, marie-kathrin.breyer@oncolbilh.com
Piotr Cichon, +431 91060 42008, piotr.cichon@gesundheitsverbund.at
- Recruiting
Ludwig Boltzmann Institut for Lung Health
Vienna, 1140
Marie-Kathrin Breyer, 019106042002, marie-kathrin.breyer@oncolbilh.com
Robab Breyer-Kohansal, +431 80110 2471, robab.breyer-kohansal@lunghealth.lbg.ac.at
- Recruiting
Klinik Ottakring
Vienna, 1160
Georg-Christian Funk, +431 49150 2201, georg-christian.funk@gesundheitsverbund.at
Sophie Marie Rundel, sophiemarie.rundel@gesundheitsverbund.at
- Recruiting
Klinik Floridsdorf
Vienna, 1210
Arschang Valipour, +431 27700 72208, arschang.valipour@gesundheitsverbund.at
Mathis Hochrainer, mathis.hochrainer@gesundheitsverbund.at
About this study
The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.
There are no additional interventions regarding this registry.
- Conditions
- Interstitial Lung Disease
- Medical subject headings
- Lung Diseases, Interstitial
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Mortality caused by interstitial lung disease
Measured: 10 years
Loss of lung function
FVC and DLCO loss within 24 months
Measured: 2 years
Secondary outcomes (2)
Prevalence
Prevalence of the different interstitial lung diseases in Austria
Measured: 10 years
Response to drugs
Response to immunosuppressive/immunomodulating/antifibrotic drugs
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2024
- Study start28 Feb 2024
- Primary completion28 Feb 2034 (estimated)
- Study completion28 Feb 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 400 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Ludwig Boltzmann Institute for Lung Health
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Robab Breyer-Kohansal, Ludwig Boltzmann Institute for Lung Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06522334
- Sponsor's protocol ID
- ILD Registry
- Status last verified
- Mar 2025
- First submitted
- 22 Jul 2024
- Last updated
- 14 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria
- ClinicalTrials.gov ID
- NCT06522334
- Acronym / sponsor ID
- ILD Registry
- Conditions
- Interstitial Lung Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Ludwig Boltzmann Institute for Lung HealthUniversity, hospital or other
- Study start
- 28 Feb 2024 (actual)
- Primary completion
- 28 Feb 2034 (estimated)
- Study completion
- 28 Feb 2034 (estimated)
- First posted
- 26 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.
There are no additional interventions regarding this registry.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Everybody with a diagnosis of interstitial lung disease, over 18 years old will be asked to participate.
Key inclusion criteria (2 listed)
- diagnosis of interstitial lung disease
- written informed consent
Key exclusion criteria (1 listed)
- to not comprehend and rightfully judge participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality
Time frame: 10 years
Mortality caused by interstitial lung disease
Loss of lung function
Time frame: 2 years
FVC and DLCO loss within 24 months
2 secondary outcomes
Prevalence
Time frame: 10 years
Response to drugs
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2025.
Related trials for Interstitial Lung Disease
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
RecruitingObservational study
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Erdheim-Chester Disease
RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Not yet recruitingPhase 2
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ludwig Boltzmann Institut for Lung Health
Vienna, Austria
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Disease, run by Ludwig Boltzmann Institute for Lung Health at 5 sites in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2025.